```html

Quebec Platelet Disorder – A Comprehensive Medical Guide

Overview

Quebec platelet disorder (QPD) is a rare, inherited bleeding disorder caused by a genetic duplication that leads to excessive release of the enzyme urokinase‑type plasminogen activator (uPA) from platelet alpha‑granules. The over‑activity of uPA increases clot breakdown (fibrinolysis) within the platelet plug, resulting in a tendency to bleed despite a normal platelet count.

Who it affects: QPD follows an autosomal‑dominant inheritance pattern, meaning a single copy of the altered gene is enough to cause disease. Both males and females are affected, and symptoms typically appear in childhood or early adulthood, although some people remain asymptomatic until a surgical challenge or trauma.

Prevalence: As of the most recent epidemiological data, QPD has been identified in roughly 5–10 families worldwide, with an estimated prevalence of < 1 per 1 million individuals. The disorder is named after the province of Quebec, Canada, where the first affected families were described in the 1970s.

Symptoms

Because QPD does not affect platelet number, the principal clinical problem is abnormal bleeding. The severity is highly variable.

• Nosebleeds (epistaxis) – often recurrent, may be prolonged.
• Bleeding gums – especially after dental work or brushing.
• Easy bruising – large, spontaneously appearing ecchymoses after minor trauma.
• Heavy menstrual bleeding (menorrhagia) – common in women of reproductive age.
• Post‑operative bleeding – disproportionate bleeding after surgeries such as tonsillectomy, circumcision, or orthopedic procedures.
• Hematuria – blood in the urine after vigorous exercise or trauma.
• Prolonged bleeding after dental extractions or orthodontic procedures.
• Hemarthrosis (bleeding into joints) – rare but reported after significant joint trauma.
• Intracranial hemorrhage – extremely rare; usually linked to severe trauma.

Patients may also experience “platelet storage‑pool”–like symptoms (e.g., delayed bleeding 6–12 hours after injury) because the fibrinolytic process continues after the initial clot forms.

Causes and Risk Factors

Genetic cause

QPD results from a tandem duplication of exons 10–16 in the PLAUR gene on chromosome 19q13.2. The duplication leads to over‑expression of the uPA protein in platelets. The mutation is inherited in an autosomal‑dominant fashion with ≈50 % transmission risk to offspring.

Risk factors

• Positive family history – at least one first‑degree relative with confirmed QPD.
• European ancestry – most reported families originate from French‑Canadian or Northern European descent, though cases worldwide have been documented.
• Gender – women may manifest earlier due to menstrual bleeding, but the underlying risk is equal.
• Trauma or surgery – these are triggers that reveal the bleeding tendency.

Diagnosis

Because routine blood counts are normal, a high index of suspicion is needed.

Step‑wise approach

1. Clinical history and family pedigree – detailed bleeding questionnaire (e.g., ISTH Bleeding Assessment Tool).
2. Basic laboratory testing
   • Complete blood count (CBC) – usually normal platelet count.
   • Prothrombin time (PT) and activated partial thromboplastin time (aPTT) – typically within reference.
   • Platelet function analyzer (PFA‑100) – may be normal.
3. Specialized platelet studies
   • Platelet aggregometry – often shows normal aggregation to ADP, collagen, ristocetin, but delayed or reduced response due to fibrinolysis.
   • Urokinase‑type plasminogen activator (uPA) assay – markedly elevated uPA release from stimulated platelets is the hallmark.
   • Fibrin clot lysis assay – demonstrates accelerated clot breakdown.
4. Genetic testing – sequencing or duplication analysis of the PLAUR gene confirms the diagnosis. Commercial panels for inherited bleeding disorders now include QPD.

According to the CDC’s genetic testing guidelines, confirming a pathogenic PLAUR duplication is considered definitive.

Treatment Options

Treatment is individualized, focusing on preventing or controlling bleeding episodes.

1. Antifibrinolytic agents

• Tranexamic acid (TXA) – 10–15 mg/kg orally every 8 hours (or 1 g IV over 10 min) before dental work, surgery, or heavy menses.
• Aminocaproic acid – alternative when TXA is not tolerated.

Both agents inhibit plasmin formation, directly counteracting the excess uPA activity.

2. Platelet transfusion

Useful for life‑threatening bleeding or when antifibrinolytics are insufficient. Fresh–frozen plasma may also be given to supply additional clotting factors, although it does not correct the platelet defect.

3. Desmopressin (DDAVP)

Shows limited benefit because the problem is fibrinolysis rather than a deficiency of von Willebrand factor or factor VIII. Some clinicians use a trial dose for minor mucosal bleeds.

4. Hormonal therapy for women

• Combined oral contraceptives or levonorgestrel‑intrauterine systems can reduce menorrhagia.
• Tranexamic acid during the first 1–2 days of menses is also effective.

5. Surgical considerations

Pre‑operative planning should include:

• TxA 1 hour before incision and continued for 24‑48 hours post‑op.
• Readiness for platelet transfusion.
• Avoidance of unnecessary invasive procedures.

6. Lifestyle & supportive measures

• Prompt treatment of minor cuts with pressure and topical hemostatics.
• Regular dental prophylaxis to minimise gum bleeding.
• Use of protective gear during contact sports.

Living with Quebec Platelet Disorder

Daily management tips

• Maintain a bleeding diary – record any bruises, nosebleeds, or menstrual changes. This helps clinicians adjust therapy.
• Carry medical identification – a bracelet or card indicating “Quebec Platelet Disorder – requires antifibrinolytic therapy” can expedite care.
• Plan ahead for procedures – inform dentists, surgeons, and anesthesia teams well before any planned intervention.
• Oral hygiene – gentle brushing with a soft‑bristled toothbrush and regular flossing reduce gum trauma.
• Nutrition – adequate vitamin C and K intake supports vascular integrity; no specific diet is required.
• Exercise – moderate activity is encouraged, but avoid high‑impact sports that increase risk of deep tissue bruising.
• Support groups – connect with rare‑bleeding‑disorder communities (e.g., the Rare Bleeding Disorders Consortium) for emotional support.

Prevention

Because QPD is genetic, primary prevention (preventing the disease) isn’t possible, but secondary prevention—reducing bleeding episodes—is achievable.

• Genetic counseling for families planning children.
• Early identification of carriers through targeted testing.
• Prophylactic use of TXA before known high‑risk events (e.g., dental cleaning, surgery).
• Vaccination against hepatitis B and C to avoid liver disease that could compound bleeding risks.
• Regular follow‑up with a hematologist experienced in inherited bleeding disorders.

Complications

If left untreated or poorly managed, QPD can lead to:

• Iron‑deficiency anemia from chronic gastrointestinal or menstrual bleeding.
• Hemorrhagic shock during major surgery or severe trauma.
• Recurrent joint damage from repeated hemarthroses, potentially leading to early osteoarthritis.
• Psychosocial impact – anxiety or depression related to unpredictable bleeding.
• Pregnancy complications – postpartum hemorrhage risk is increased; coordinated obstetric‑hematology care is essential.

When to Seek Emergency Care

References

• Mayo Clinic. “Bleeding disorders.” https://www.mayoclinic.org.
• National Institutes of Health. “GeneReviews®: Quebec Platelet Disorder.” https://www.ncbi.nlm.nih.gov.
• World Health Organization. “Guidelines on the Diagnosis and Management of Rare Bleeding Disorders.” WHO, 2022.
• Cleveland Clinic. “Antifibrinolytic Therapy (Tranexamic Acid).” https://my.clevelandclinic.org.
• American Society of Hematology. “Management of Inherited Platelet Function Disorders.” Blood, 2021; 138(19): 1794‑1809.
• CDC. “Genetic Testing for Inherited Bleeding Disorders.” https://www.cdc.gov.

```